Global Trust Asset Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Global Trust Asset Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-325	Closed	-$227K	–	461
2022 Q1	$227K	Buy	+325	New	+$206K	0.09%	163
2020 Q2	–	Sell	-700	Closed	-$331K	–	395
2020 Q1	$331K	Buy	+700	New	+$289K	0.26%	101
2019 Q4	–	Sell	-5	Closed	-$1K	–	413
2019 Q3	$1K	Hold	5	–	–	﹤0.01%	348
2019 Q2	$2K	Hold	5	–	–	﹤0.01%	358
2019 Q1	$2K	Hold	5	–	–	﹤0.01%	334
2018 Q4	$2K	Hold	5	–	–	﹤0.01%	346
2018 Q3	$2K	Buy	+5	New	+$1.9K	﹤0.01%	382

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Global Trust Asset Management's REGN Position: Q2 2022 in Review

Global Trust Asset Management sold out of Regeneron Pharmaceuticals (REGN) in Q2 2022, closing a stake of 325 shares — an estimated $227K sold.

Global Trust Asset Management first reported a position in REGN in Q3 2018 and held it in 7 quarters. The position peaked at $331K in Q1 2020. 1,064 funds tracked by Wall St. Rank hold REGN as of Q2 2022.

Global Trust Asset Management reported no remaining Regeneron Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
Global Trust Asset Management sold 325 Regeneron Pharmaceuticals shares in Q2 2022, an estimated $227K.
Global Trust Asset Management first reported a position in Regeneron Pharmaceuticals in Q3 2018 and held it in 7 quarters.
Global Trust Asset Management's Regeneron Pharmaceuticals position peaked at $331K in Q1 2020.
1,064 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2022.

Based on Global Trust Asset Management's 13F filing for Q2 2022, filed 12 Jul 2022.